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OBJECTIVES: Databases contain large numbers of unselected patients with exten-
sive medical and demographic data spanning many years. Considerable interest 
exists in using large databases to inform economic modelling. Accurate linkage 
and costing are essential to optimising their use in economic evaluation. These 
methods deliver a template to do this. Patients with Irritable bowel syndrome 
(IBS) can be diagnosed and managed entirely in primary care yet around 30% are 
referred to gastroenterology. We use routinely collected electronic records to assess 
how this referral changes total healthcare utilization and its cost. METHODS: 
Within the UK Clinical Practice Research Dataset (CPRD) we identified IBS patients 
with a first gastroenterology visit identified in linked Hospital Episode Statistics 
(HES) in 2008/9. Anyone with organic gastrointestinal disease was excluded. All 
primary care attendances and prescriptions were identified from CPRD and unit 
costs attached. Hospital inpatient stays, outpatient visits and colonoscopies were 
identified in HES. Healthcare Resource Grouping (HRG) was done via the UK NHS 
algorithm and tariff costs applied. Utilization rates and costs (2011/2012 UK £) 
per person year and ratios before and after gastroenterology visit were calculated 
and stratified. RESULTS: In 2008/9, 4811 IBS patients attended gastroenterology 
for the first time. Healthcare utilization increased in all domains before the year 
of referral and decreases after, except prescriptions which continue to increase. 
Mean total annual cost was £2492 three years before referral and £3352 three 
years after (£807 and £821 respectively excluding prescription costs). Costs were 
greatest in older patients, those in lower socioeconomic groups, smokers and 
those diagnosed with IBS less than a year. CONCLUSIONS: Complete primary 
and secondary healthcare utilization and costs can accurately be calculated at 
individual and cohort level using routinely collected data from large databases 
and tariff prices. These data could be used directly in economic modelling from 
the payer’s perspective and to inform policy.
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OBJECTIVES: To analyze the utilization of ERCP-related operations and medical 
supplies as well as their expenses and payment in China BMI inpatients, and 
determine whether the BMI payment policies are appropriate for these inpa-
tients. METHODS: This study used the data from the National Sample Survey 
on Medical Service Utilization of the BMI participants in 2012. Altogether 10,597 
inpatients (2.2% of total) treated by ERCP technologies were extracted from the 
375 thousands total sample inpatients of all over the country. All the actual 
claim data of medical expenses and medical care utilization were collected. 
Descriptive analysis was applied to the data and related BMI payment policies 
were reviewed. RESULTS: 1) About 948 thousands inpatients were treated by ERCP 
technologies in China BMI participants in 2011, 83% of them suffered from the 
digestive system diseases. 2) The average hospitalization medical expenses of 
ERCP inpatients was 11293 RMB (about 1820 USD), among which 45%, 40% and 
15% were for drugs, medical services and medical supplies respectively. 3) The 32 
ERCP-related operations cost more than 414 million RMB (about 67 million USD), 
and Top 5 high-cost operations cost 80.4%. 4) The 16 ERCP-related medical supplies 
cost 194 million RMB (about 31 million USD) and Top 5 cost 58%. The highest price 
of these medical supplies was more than 7500 RMB (about 1210 USD, i.e. enteral 
stent). 5) The average reimbursement rate of ERCP inpatients about 68%, 5 percents 
lower than that of total BMI inpatients. CONCLUSIONS: The ERCP technologies 
were effective new diagnosis and treatment methods used more widely in clinical 
practice at present. The medical expenses of ERCP-related inpatients were higher, 
while their BMI reimbursement level was lower, which meant that their economic 
burden were higher but could get less reimbursement from BMI. The BMI reim-
bursement policies on the ERCP-related operations and medical supplies should 
be adjusted to promote these new medical technologies.
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OBJECTIVES: To estimate colorectal cancer (CRC) -attributable cost in the United 
States by quantifying the direct medical cost of cancer care for CRC patients and 
to study the effects of CRC on direct healthcare costs. METHODS: We used direct 
medical cost data from the household component of the Medical Expenditure Panel 
Surveys (MEPS) of 2008 to 2012that gather healthcare utilization and expenditures 
for the US civilian non-institutionalized population. To estimate CRC-attributable 
cost, patients reporting a past CRC diagnosis were matched with non-cancer 
controls on age, region, poverty level, race, insurance status, and marital status. 
Generalized linear model (GLM) was chosen to model costs. RESULTS: An average 
of 110 persons in each year reported a prior CRC diagnosis.The mean annual direct 
medical cost attributable to CRC was $18,240 in 2008, $18,211 in 2009, $11,192 in 
2010, $11,113 in 2011 and $13,301 in 2012. Applying the findings to SEER estimates of 
population-wide CRC prevalence, CRC attributable costs were $27.59 billion in 2008, 
$25.45 billion in 2009, $14.11 billion in 2010, $13.03 billion in 2011 and $15.08 billion 
in 2012, a trend consistent with the documented overall healthcare cost decline 
following the 2008-09 recession. CONCLUSIONS: Our study revealed a significant 
decline in annual CRC attributable cost in 2010. Our findings may be confounded by 
5-plus year survivors who may no longer qualify as “cancer” patients, and by stage 
at diagnosis among the study sample. Localized disease is associated with a 90% 
5-year survival rate. Study limitations include: a) a lack of consistent data on time 
since cancer diagnosis which is relevant to cancer care cost computations, and, b) 
lack of data on stage at diagnosis. With about 130,000 new cases each year, additional 
research is warranted to develop accurate cost estimates.
OBJECTIVES: An increase of financial risk in healthcare is associated with many issues 
such as poor quality of hospital care, bureaucratic management methods used in state 
hospitals, low remuneration of health professionals, financing based on not real costs 
of services and almost absence of procurement activities in hospitals. The aim of the 
study was to estimate outpatient and inpatient care costs in provincial general hos-
pitals. METHODS: We were using top down cost estimation method. Total eight pro-
vincial hospitals participated in the study. RESULTS: Generally, 51 percent of the total 
costs was spent for inpatient medical care, 11 percent was spent on outpatient care, 
5 percent was spent on emergency care, 18 percent was spent for additional services 
and 18 percent were for management costs. In Umnugobi provincial general hospital 
there were 455 outpatients per employee, whereas 200 outpatients per employee were 
in Dornod provincial general hospital. There were 34 and 17 inpatients per employee 
at Khovd provincial general hospital and Tov provincial general hospital respectively 
whereas the average was 27. Day surgery costs were the highest, 248.583 MNT, and 
the lowest costs were for eye outpatient, 7270 MNT. The highest costs were average 
emergency care cost, 2 028 966 MNT, and tuberculosis treatment costs, 1 895 340 MNT. 
Average cost of inpatient care was 574 236 MNT. CONCLUSIONS: In average only 11 
percent of hospital budget was spent on emergency care, which was insufficient. 
Umnugobi provincial general hospital employees had by 44.3 percent higher work-
load compared to Dornod provincial general hospital employees. Khovd Diagnostic 
and Treatment Regional Centre Hospital’s inpatient workload per employee was 50 
percent higher compare to Tov provincial general hospital.
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OBJECTIVES: To describe and compare the first hospitalization cost and the readmis-
sion cost of Ischemic Stroke (IS) patients at Beijing urban area. METHODS: Retrospective 
data on hospitalization of IS was selected from Beijing urban employees and residents 
medical insurance database. We randomly selected 10% of patients first diagnosed as 
IS during January 2012- December, 2012and then followed those patients to September 
2013. 4504 patients were identified in our study and then 2371 patients reoccurred dur-
ing the observation period. All information of patient demographic characters, length 
of stay and clinical costs were collected. The descriptive statistics were used in the 
data analysis. The costs of 2013 were converted into 2012 year price with discount 
rate 3.5%. RESULTS: We analyzed the 2371 patients with recurrence of IS,(mean age 
69.482±13.68 years; 64.78% male), among which 1448 patients(61%) were readmitted 
to hospital over three times. The median followed time was 15.6 months ( IQR12.37-
18.6, mean15.86±3.69). The median hospitalization cost was ￥13794.16 (IQR9659.26-
20529.71, mean 19933.24±23253.07)at the first time, ￥13710 (IQR9580.68-20907.06, mean 
19682.76±23163.26) at the second time, and ￥13977.03 (IQR 9831.29- 21631.75, mean 
19893.81±21848.2)at the third time or more, respectively(P< 0.05). The median length 
of stay was 15 days (IQR 11-21, mean 17.89±12.73) in the first hospitalization, 15 days 
(IQR 11-22, mean 18.18±12.64) in the second hospitalization and 15 days(IQR11-23,mean 
18.82±13.15) in the third hospitalization or more, respectively(p< 0.05). CONCLUSION
S: Patients with readmission took a high percentage of all hospitalized IS patients and 
caused heavy hospitalization cost. Hospitalizations of the second time had shorter 
length of stay than those at the first hospitalization and the third or more, total hospi-
talization cost of different admissions showed no significant difference.
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OBJECTIVES: Hepatitis C (HCV) is a curable disease that affects roughly 242,000 
Canadians and 24,000 Albertans. Without treatment, those infected may develop 
cirrhosis, hepatocellular cancer (HCC) and irreversible decompensated cirrhosis 
(DCC). This study examines the current Alberta “market” for HCV-related services. 
Little is currently known about the segmentation of providers within this market 
or the degree to which these segments of providers are integrated into the overall 
HCV services market. The expenditure required to fund various HCV service seg-
ments is also unknown. METHODS: We conducted a costing analysis to estimate 
the expenditure required to fund the current HCV services market and its various 
segments in Alberta. In order to conduct this analysis, it was necessary to describe 
the current market associated with different segments of care for HCV. Information 
was obtained from the literature and through consultation with health care profes-
sionals involved in providing HCV-related services. RESULTS: Six segments were 
identified within the overall HCV service market. These included prevention, screen-
ing, early treatment, later treatment for advanced liver disease (including liver trans-
plant), and finally end stage liver disease (ESLD). The estimated cost for HCV-related 
services overall was $47 million (CAD$) per year. Late and ESLD were associated 
with a cumulative cost of $17.8 million ($8.5 million for late stage and $9.3 million 
for ESLD). Treatment with antivirals (i.e., early segment) was associated with $15 
million in costs. CONCLUSIONS: Costs in Alberta will likely increase in the future 
because of the current lack of integration across HCV service provider segments 
such as screening and early treatment referral. System capacity limitations for 
early treatment and liver transplants will also contribute to future increases in cost.
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